A new drug combo is offering hope for men with advanced prostate cancer.
Adding the targeted cancer drug niraparib to hormone therapy reduced the risk of prostate tumor growth and slowed symptom advance, researchers wrote in findings published Tuesday in the journal Nature Medicine.
The combination was even more effective among men with genetic mutations driving their prostate cancer, researchers noted.
"Although current standard treatments are very effective for the majority of patients with advanced prostate cancer, a small but very significant proportion of patients have limited benefit," said lead researcher Dr. Gerhardt Attard, chair of medical oncology with the University College London Cancer Institute.
Related
